What Is Pluvicto Approved For? Label Indications, Per the Research

Pluvicto (lutetium Lu 177 vipivotide tetraxetan) is a prescription medicine, and it is approved. Published regulatory literature records that the US Food and Drug Administration approved it on March 23, 2022 for adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who had been treated with androgen receptor pathway inhibition and taxane-based chemotherapy (PMID 36469000). A 2022 drug-approval profile described the same event as the agent's first approval anywhere, granted for metastatic castration-resistant prostate cancer (PMID 35553387). This page summarises what the published literature says about that indication; it does not describe how the medicine is given.

This page is for educational purposes only and is not medical advice; consult a licensed physician about whether any approved therapy is appropriate for a particular person. Nothing here is a substitute for the current approved labelling, which a prescribing clinician and the regulator maintain.

The approved indication, as described in the approval literature

The FDA approval summary published in Clinical Cancer Research set out the three elements that together define the approved population: metastatic castration-resistant prostate cancer, PSMA positivity established by imaging, and prior treatment with both an androgen receptor pathway inhibitor and taxane-based chemotherapy (PMID 36469000). A 2023 drug monograph in Drugs of Today likewise framed the agent as a radioligand therapy approved for prostate cancer that targets PSMA on tumour cells (PMID 36811416).

Each element, unpacked

• Metastatic castration-resistant prostate cancer. A 2022 expert review described the agent specifically in the mCRPC setting — disease that has spread and has progressed despite testosterone suppression (PMID 36305305).
• PSMA-positive by imaging. The approval summary noted that patient selection depended on PSMA-positive lesions identified on PSMA-targeted imaging, which is why the therapy is described as part of a theranostic pairing (PMID 36469000). A 2026 review of theranostics in nuclear medicine placed this imaging-then-treating sequence at the centre of how such agents are regulated and evaluated (PMID 42097922).
• Prior therapy requirement. The approval summary recorded that the approved population had already received androgen receptor pathway inhibition and taxane-based chemotherapy (PMID 36469000).

Approval timeline in the published record

Approved labelling is revised over time, and regional regulators maintain their own wording. The dates above reflect what the cited publications reported at the time they were written; the current, authoritative indication for any jurisdiction sits in the regulator-approved product information and is a matter for a prescribing clinician.

The evidence base behind the indication

The FDA approval summary explained that the approval rested on a randomised trial in men with PSMA-positive mCRPC who had progressed after androgen receptor pathway inhibition and taxane chemotherapy, in which researchers reported improvements in overall survival and radiographic progression-free survival relative to the comparator arm (PMID 36469000). The 2022 approval profile reached the same characterisation of the registrational data supporting first approval (PMID 35553387).

Independent syntheses have since examined the same question. A 2024 analysis published in JAMA Network Open compared lutetium-177 PSMA radioligand therapy with comparator treatments for survival outcomes in metastatic castration-resistant prostate cancer, pooling the available randomised evidence (PMID 39287944). The 2022 expert review summarised the clinical development pathway that led from early PSMA-targeted radioligand work to a licensed product (PMID 36305305).

Health-economic work sits alongside the clinical evidence but does not change an indication. A 2023 cost-effectiveness analysis in JNCCN modelled 177Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer to inform value discussions (PMID 36634610). Analyses of that kind feed into coverage and reimbursement conversations, which are separate from what a regulator has authorised.

Safety in the approved setting: What Studies Report

The FDA approval summary reported that the adverse reactions observed most often in the registrational setting included fatigue, dry mouth, nausea, anaemia, decreased appetite and constipation, and that myelosuppression was among the toxicities requiring monitoring (PMID 36469000). The 2023 monograph in Drugs of Today described a comparable tolerability picture for the approved radioligand therapy in prostate cancer (PMID 36811416), and the 2022 expert review discussed the same class-related considerations, including radiation-safety handling that distinguishes radiopharmaceuticals from conventional oncology drugs (PMID 36305305).

Post-marketing surveillance has added a different lens. A real-world disproportionality analysis of the FDA Adverse Event Reporting System compared reported safety signals for enzalutamide, olaparib and lutetium Lu-177 vipivotide tetraxetan in patients with prostate cancer, and researchers described differing signal profiles across the three agents (PMID 42446704). Disproportionality analyses detect reporting patterns rather than establish causation, and the study was framed as hypothesis-generating signal detection.

A 2026 review of the radiopharmaceutical regulatory landscape noted that products of this class carry handling, dosimetry and facility requirements layered on top of ordinary drug regulation (PMID 41741857), and the 2026 theranostics review made a similar point about the specialist infrastructure that administration requires (PMID 42097922).

What is not an approved indication

Everything outside the licensed wording is, by definition, either off-label use or ongoing investigation. The literature cited here does not describe approval for any of the following, and none of them should be read as authorised uses:

• Hormone-sensitive or non-castration-resistant prostate cancer. The approval literature defined the population as castration-resistant and metastatic (PMID 36469000).
• Localised or non-metastatic disease. The 2022 review discussed the agent in the metastatic setting only (PMID 36305305).
• PSMA-negative disease. PSMA positivity on imaging was integral to patient selection in the approval summary (PMID 36469000).
• Other PSMA-expressing tumour types. Work on novel PSMA-targeting radionuclide peptidomimetics for prostate cancer has been described as preclinical chemistry and biology rather than licensed therapy (PMID 36655127).

Clinical trials continue to test PSMA radioligand therapy in earlier treatment lines and in combination strategies. Trial participation and label expansion are different things: a positive trial does not alter an indication until a regulator amends the labelling, a sequencing point the 2026 theranostics review emphasised when describing how evidence moves into practice (PMID 42097922).

How this indication sits among other prostate cancer medicines

Approved prostate cancer therapies occupy distinct labelled positions. Relugolix, for example, was reviewed in 2022 as an oral gonadotropin-releasing hormone antagonist used in the management of prostate cancer through androgen suppression — a mechanism and setting entirely separate from PSMA-targeted radioligand therapy (PMID 35866612). The FAERS comparison study similarly treated enzalutamide, olaparib and the lutetium-177 radioligand as three different therapeutic categories with different reported event profiles (PMID 42446704).

That separation matters when reading about "prostate cancer drugs" as a group: an approval granted to one agent says nothing about another. The 2022 nursing-literature notice introduced the radioligand specifically as a new option in the castration-resistant metastatic setting rather than as a general prostate cancer treatment (PMID 35736599).

Why the imaging requirement is part of the indication

PSMA-targeted radioligand therapy is usually described as a theranostic: the same molecular target used to image disease is used to deliver radiation to it. The approval summary tied eligibility to PSMA-positive lesions demonstrated on imaging (PMID 36469000), and the 2026 theranostics review set out the historical and regulatory context in which diagnostic and therapeutic pairs came to be authorised together (PMID 42097922). The 2026 radiopharmaceutical regulatory review described the broader framework governing manufacture, supply and oversight of such products (PMID 41741857).

Questions that belong with a prescribing clinician

Published literature can describe what a regulator authorised and what trials measured. It cannot determine whether a particular person meets the labelled criteria. The following are clinician questions, not literature questions:

1. Whether imaging shows PSMA-positive disease that fits the labelled description.
2. Whether prior therapy history matches the approved sequence described in the approval summary (PMID 36469000).
3. How renal function, marrow reserve and other comorbidities interact with the toxicities the reviews reported (PMID 36305305).
4. What the currently approved labelling says in the relevant country, which may differ from the 2022 snapshot captured in these publications (PMID 35553387).

Key takeaways from the cited literature

• Pluvicto is a prescription medicine approved in the United States in March 2022 for PSMA-positive mCRPC after androgen receptor pathway inhibition and taxane-based chemotherapy (PMID 36469000, PMID 35553387).
• Randomised evidence supporting that approval showed survival and radiographic progression-free survival advantages over the comparator arm, as the approval summary reported (PMID 36469000), with later pooled analysis revisiting the comparison (PMID 39287944).
• Commonly reported adverse reactions in the approval literature included fatigue, dry mouth, nausea, anaemia, decreased appetite and constipation (PMID 36469000).
• Uses outside the labelled population remain investigational in the cited record (PMID 36655127).

References

• FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer (Clinical Cancer Research, 2023)
• Lutetium Lu 177 Vipivotide Tetraxetan: First Approval (Molecular Diagnosis & Therapy, 2022)
• Lutetium Lu 177 vipivotide tetraxetan for prostate cancer (Drugs of Today, 2023)
• Lutetium Lu 177 vipivotide tetraxetan for metastatic castration-resistant prostate cancer (Expert Review of Anticancer Therapy, 2022)
• Lu-177 PSMA vs Comparator Treatments and Survival in Metastatic Castration-Resistant Prostate Cancer (JAMA Network Open, 2024)
• Novel PSMA-Targeting Radionuclide Peptidomimetics for Treating Prostate Cancer (ACS Medicinal Chemistry Letters, 2023)
• Relugolix in the management of prostate cancer (Expert Review of Anticancer Therapy, 2022)
• Comparative safety profiles of enzalutamide, olaparib, and lutetium Lu-177 vipivotide tetraxetan in patients with prostate cancer: a real-world disproportionality analysis of the FAERS database (World Journal of Urology, 2026)
• New Drug for Metastatic Castration-Resistant Prostate Cancer (The American Journal of Nursing, 2022)
• Cost-Effectiveness Analysis of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer (JNCCN, 2023)
• Radiopharmaceuticals: Status, Regulatory Landscape and Future Perspective (AAPS PharmSciTech, 2026)
• Theranostics in Nuclear Medicine: Historical, Regulatory, and Evidence Context for the Practicing Nuclear Medicine Physician (PET Clinics, 2026)